Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting cholangiocarcinoma.

Biochimica et biophysica acta. Molecular basis of disease - 1 Apr 2018

Mertens Joachim C, Ilyas Sumera I, Gores Gregory J

Abstract excerpt

Cholangiocarcinoma (CCA) represents a diverse group of epithelial cancers associated with the biliary tract, and can best be stratified anatomically into intrahepatic (iCCA), perihilar (pCCA) and distal (dCCA) subsets. Molecular profiling has identified genetic aberrations associated with these anatomic subsets. For example, IDH catalytic site mutations and constitutively active FGFR2 fusion genes are...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Molecular Targeted Therapy
Share to Neoadjuvant Therapy
Share to Tumor Microenvironment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Epithelial Cells

Share to Bile Duct Neoplasms

Share to Bile Ducts

Share to Cancer-Associated Fibroblasts

Share to Cholangiocarcinoma

Source

Open in PubMed Open full text

Identifiers

PMID: 28844952
DOI: 10.1016/j.bbadis.2017.08.027
PMCID: PMC6013079

Genes

FGFR2
KRAS
PRKACB

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting cholangiocarcinoma.PMID 28844952Read ↗

Cholangiocarcinoma: novel therapeutic targets.Semantic proximity Read ↗

Molecular Pathogenesis of Cholangiocarcinoma: Implications for Disease Classification and Therapy.Semantic proximity Read ↗

Molecular biology of cholangiocarcinoma and its implications for targeted therapy in patient management.Semantic proximity Read ↗

The Immune–Genomics of Cholangiocarcinoma: A Biological Footprint to Develop Novel ImmunotherapiesSemantic proximity Read ↗

Developments in FGFR and IDH inhibitors for cholangiocarcinoma therapy.Semantic proximity Read ↗

The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets.Semantic proximity Read ↗

Therapy for advanced cholangiocarcinoma: Current knowledge and future potential.Semantic proximity Read ↗

Cholangiocarcinoma: molecular pathways and therapeutic opportunities.Semantic proximity Read ↗

Molecular mechanisms and genetic features of cholangiocarcinoma: implications for targeted therapeutic strategiesSemantic proximity Read ↗

Signalling networks in cholangiocarcinoma: Molecular pathogenesis, targeted therapies and drug resistanceSemantic proximity Read ↗

Evolution of Treatment in Advanced Cholangiocarcinoma: Old and New towards Precision Oncology.Semantic proximity Read ↗

Precision Oncology in Cholangiocarcinoma: Current Standards and Future DirectionsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.